Clinical trials: High-dose Chemotherapy
Triple-Negative Invasive Breast Carcinoma, Residual Tumor
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000 cases per year.
- Trial name
- NCT02670109
- Testing
- Carmustine, Cyclophosphamide, Carboplatin
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lymphoma, Myeloma
Pedometer Activity Monitoring After ASCT
The trial assess the proportion of patients who resumed their professional activity within 100 days after ASCT (autologous stem cell Transplantation).
- Conditions
- Lymphoma, Myeloma, High-dose Chemotherapy, Autologous Stem Cell Transplantation
- Trial name
- PAMAL (NCT03238599)
- Testing
- Pedometer-based activity monitoring after ASCT
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Lymphoma
Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
To determine the response rate, complete and partial, of patients with indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant.
- Trial name
- NCT00572013
- Testing
- Rituxan, BEAM, Autologous stem cell transplant
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Nebraska
Acute Myelogenous Leukemia
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
The purpose of this non-inferiority study is to compare the effectiveness of two induction chemotherapy regimens (cytarabine plus idarubicin [AI] versus cytarabine plus high-dose daunorubicin [AD]) in AML.
- Trial name
- AIvsAD (NCT01145846)
- Testing
- Cytarabine plus Daunorubicin [Arm II (AD regimen)]
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Cooperative Study Group A for Hematology
Neuralgia, Pain
Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain
The purpose of this study is to gain initial information on the tolerability of high-dose capsaicin patches in patients with Painful Postherpetic Neuralgia.
- Conditions
- Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
- Trial name
- NCT00034710
- Testing
- Capsaicin Patch
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- NeurogesX
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004088
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
The incidence rate of colorectal cancer is third in male tumors and second in female tumors. The newly diagnosed incidence of colorectal cancer is no less than 100 thousand in China, which poses a great threat to people's health…
- Trial name
- NCT05338866
- Testing
- Magnetic resonance guided radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Hodgkin's Lymphoma
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a higher response rate with the reduction of toxic side effects
- Trial name
- NCT01884441
- Testing
- Bendamustine, Gemcitabine, Vinorelbine
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- Armando Santoro, MD
Chemotherapy-induced Neutropenia
Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
Randomized, Open-Label study to determine the dose, efficacy, safety and pharmacokinetic profile of ANF-RHO™ with once-per-cycle injection in comparison with Neulasta in Breast Cancer patients at high risk of developing…
- Trial name
- NCT03559387
- Testing
- ANF-RHO™, Neulasta®
- Where
- 8 sites in France, Netherlands
- Volunteers
- 9 people
- Sponsor
- Prolong Pharmaceuticals
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Breast Cancer, Breast Neoplasms
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
Stage III patients may begin therapy prior to or following surgery. Patients with undrainable significant third space fluid collection (e.g., pleural effusions, ascites) are entered directly on Consolidation.
- Trial name
- NCT00001498
- Testing
- methotrexate, leucovorin, 5-fluorouracil
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Hypertension
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
- Trial name
- NCT01078376
- Testing
- Azilsartan medoxomil (TAK-491)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Takeda
Skin Rash
Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation
We are approaching you to participate in this study because you are taking Palifermin and the purpose of this study is to describe the effect of Palifermin on skin growth found on the body.
- Trial name
- Palifermin (NCT00610818)
- Testing
- Palifermin
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002679
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Yale University
Anemia
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
This study is a multicenter, prospective, randomized phase 3 clinical study comparing the efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin alfa + ferric derisomaltose/iron isomaltoside)…
- Trial name
- NCT05768997
- Testing
- Ferric Derisomaltose Injection, Darbepoetin Alfa Injection
- Where
- South Korea
- Volunteers
- 312 people
- Sponsor
- Hallym University Medical Center
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Primary Non Hodgkin Lymphoma of the Central Nervous System
Freiburg ZNS-NHL Study
The purpose of this study is to determine whether combined chemotherapy [rituximab plus high dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max.
- Trial name
- NCT00647049
- Testing
- methotrexate, Rituximab, Cytarabine
- Where
- Germany
- Volunteers
- 78 people
- Sponsor
- University Hospital Freiburg
Neuroblastoma, Ewings Sarcoma
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by…
- Conditions
- Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
- Trial name
- NCT00165139
- Testing
- Vincristine, Cyclophosphamide, Adriamycin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Autoimmune Diseases
Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases
While glucocorticoids and immunosuppressants ameliorate manifestations of autoimmune diseases in many patients, current therapies are insufficient to control the disease in a subset of patients, and their clinical prognosis…
- Trial name
- ASTRAD (NCT00742300)
- Testing
- Autologous hematopoietic stem cell transplantation
- Where
- Germany
- Sponsor
- Charite University, Berlin, Germany
Multiple Myeloma
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
This is an international,multicenter, prospective, open, double randomised and controlled phase III study to compare the therapeutic efficacy of tandem high dose Melphalan versus triple intermediate dose Melpahaln in…
- Trial name
- NCT00205764
- Testing
- Melphalan
- Where
- Austria
- Volunteers
- 212 people
- Sponsor
- Austrian Forum Against Cancer